Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Vogel

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Hepatology (Baltimore, Md.)|August 3, 2007
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patientsJacob Nattermann, Martin Vogel, Thomas Berg, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
European Journal of Haematology|June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trialsChristian Straka, Stefan Knop, Martin Vogel, et al.
The Journal of Infectious Diseases|January 25, 2011
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis CJacob Nattermann, Martin Vogel, Hans Dieter Nischalke, et al.
The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2003
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative studyLuz Martín-Carbonero, Yves Benhamou, Massimo Puoti, et al.
Gastroenterology|May 8, 2009
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with menThijis van de Laar, Oliver Pybus, Sylvia Bruisten, et al.
AIDS (London, England)|December 20, 2003
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infectionMarcus Altfeld, Marylyn M Addo, Eric S Rosenberg, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Current Medical Research and Opinion|July 14, 2021
Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 28, 2022
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple MyelomaKatja Weisel, Amrita Krishnan, Jordan M Schecter, et al.
Hepatology (Baltimore, Md.)|August 3, 2007
Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patientsJacob Nattermann, Martin Vogel, Thomas Berg, et al.
Ejhaem|July 18, 2022
Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myelomaThomas Martin, Amrita Krishnan, Kwee Yong, et al.
European Journal of Haematology|June 25, 2019
Bortezomib consolidation following autologous transplant in younger and older patients with newly diagnosed multiple myeloma in two phase III trialsChristian Straka, Stefan Knop, Martin Vogel, et al.
The Journal of Infectious Diseases|January 25, 2011
Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis CJacob Nattermann, Martin Vogel, Hans Dieter Nischalke, et al.
The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2003
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative studyLuz Martín-Carbonero, Yves Benhamou, Massimo Puoti, et al.
Gastroenterology|May 8, 2009
Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with menThijis van de Laar, Oliver Pybus, Sylvia Bruisten, et al.
AIDS (London, England)|December 20, 2003
Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infectionMarcus Altfeld, Marylyn M Addo, Eric S Rosenberg, et al.
Pageof 12